XML 19 R7.htm IDEA: XBRL DOCUMENT
v3.6.0.2

Note 1 - Organization and Business | 12 Months Ended
--- | ---
Dec. 31, 2016
Notes to Financial Statements |
Business Description and Basis of Presentation [Text Block] |
1. | Organization and Business
Heron Therapeutics, Inc. (the “Company”, “Heron”, or “we”) is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs. We are developing novel, patient-focused solutions that apply our innovative science and technologies to already-approved pharmacological agents. On August 9, 2016, our first commercial product, SUSTOL ® (granisetron) extended-release injection (“SUSTOL”), was approved by the U.S. Food and Drug Administration (“FDA”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide combination chemotherapy regimens. We commenced commercial sales of SUSTOL in October 2016. We have two investigational pharmaceutical products for patients suffering from cancer or post-operative pain. CINVANTI™ ( HTX- 019), an intravenous formulation of the neurokinin- 1 receptor antagonist aprepitant, has been developed for the prevention of chemotherapy-induced nausea and vomiting as an adjunct to other antiemetic agents. HTX- 011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. We have incurred significant operating losses and negative cash flows from operations. As of December 31, 2016, our accumulated deficit was $586.0 million and we had $51.1 million in cash, cash equivalents and short-term investments. In January 2017, we completed an underwritten public offering of our common stock for net proceeds of $163.7 million. As of December 31, 2016, our pro-forma cash, cash equivalents and short-term investments, adjusting for the January 2017 public offering, was $214.8 million. Based on our current operating plan and projections, management believes that available cash, cash equivalents and short-term investments are sufficient to fund operations for at least one year from the date this annual report on Form 10 -K is filed with the U.S. Securities and Exchange Commission (the “SEC”).

X
- Definition The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + References No definition available. + Details
Name: | us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration